AIMS: Nevirapine (NVP) is a non-nucleoside reverse transcriptase inhibitor used for chronic human immunodeficiency virus infections in adults and children. The aims of this study were to investigate the population pharmacokinetics of NVP in children, establish factors that influence NVP pharmacokinetics and evaluate the current dosing recommendations. METHODS: Concentrations were measured on a routine basis in 94 children aged from 2 months to 17 years. A total of 390 NVP plasma concentrations were retrospectively collected, and a population pharmacokinetic model was developed with Monolix 4.0. RESULTS: Nevirapine pharmacokinetics was best described by a one-compartment model with first-order absorption and elimination. After standardization to a 70 kg adult using allometry, postmenstrual age had a significant effect on the bioavailability. Estimates of apparent clearance and volume of distribution were 3.9 l h(-1) (70 kg)(-1) and 140 l (70 kg)(-1) , respectively. Based on simulations of European Medicines Agency (EMA) and World Health Organization (WHO) dosing recommendations, the probability of observing minimal concentrations below the efficacy target of 3 mg l(-1) is higher following the EMA recommendations than the WHO recommendations. However, NVP underdosing persists for the 3-6 and 6-10 kg weight ranges following the WHO recommendations. CONCLUSIONS: It is suggested to increase doses to 75 and 100 mg twice daily for the 3-6 and 6-10 kg weight ranges, respectively, in order to obtain more than 95% of children with concentrations above 3 mg l(-1) .
AIMS: Nevirapine (NVP) is a non-nucleoside reverse transcriptase inhibitor used for chronic human immunodeficiency virus infections in adults and children. The aims of this study were to investigate the population pharmacokinetics of NVP in children, establish factors that influence NVP pharmacokinetics and evaluate the current dosing recommendations. METHODS: Concentrations were measured on a routine basis in 94 children aged from 2 months to 17 years. A total of 390 NVP plasma concentrations were retrospectively collected, and a population pharmacokinetic model was developed with Monolix 4.0. RESULTS:Nevirapine pharmacokinetics was best described by a one-compartment model with first-order absorption and elimination. After standardization to a 70 kg adult using allometry, postmenstrual age had a significant effect on the bioavailability. Estimates of apparent clearance and volume of distribution were 3.9 l h(-1) (70 kg)(-1) and 140 l (70 kg)(-1) , respectively. Based on simulations of European Medicines Agency (EMA) and World Health Organization (WHO) dosing recommendations, the probability of observing minimal concentrations below the efficacy target of 3 mg l(-1) is higher following the EMA recommendations than the WHO recommendations. However, NVP underdosing persists for the 3-6 and 6-10 kg weight ranges following the WHO recommendations. CONCLUSIONS: It is suggested to increase doses to 75 and 100 mg twice daily for the 3-6 and 6-10 kg weight ranges, respectively, in order to obtain more than 95% of children with concentrations above 3 mg l(-1) .
Authors: R P van Heeswijk; A I Veldkamp; J W Mulder; P L Meenhorst; F W Wit; J M Lange; S A Danner; N A Foudraine; M O Kwakkelstein; P Reiss; J H Beijnen; R M Hoetelmans Journal: AIDS Date: 2000-05-26 Impact factor: 4.177
Authors: Mark Mirochnick; Alejandro Dorenbaum; Suzette Blanchard; Coleen K Cunningham; Richard D Gelber; Lynne Mofenson; Mary Culnane; John L Sullivan Journal: J Acquir Immune Defic Syndr Date: 2003-06-01 Impact factor: 3.731
Authors: Avinash K Shetty; Hoosen M Coovadia; Mark M Mirochnick; Yvonne Maldonado; Lynne M Mofenson; Susan H Eshleman; Thomas Fleming; Lynda Emel; Kathy George; David A Katzenstein; Jennifer Wells; Charles C Maponga; Anthony Mwatha; Samuel Adeniyi Jones; Salim S Abdool Karim; Mary T Bassett Journal: J Acquir Immune Defic Syndr Date: 2003-12-15 Impact factor: 3.731
Authors: K Luzuriaga; Y Bryson; G McSherry; J Robinson; B Stechenberg; G Scott; M Lamson; S Cort; J L Sullivan Journal: J Infect Dis Date: 1996-10 Impact factor: 5.226
Authors: Gwenda Verweel; Mike Sharland; Hermione Lyall; Vas Novelli; Diane M Gibb; Gillian Dumont; Colin Ball; Ed Wilkins; Sam Walters; Gareth Tudor-Williams Journal: AIDS Date: 2003-07-25 Impact factor: 4.177
Authors: Theodora E M S de Vries-Sluijs; Jeanne P Dieleman; Dennis Arts; Alwin D R Huitema; Jos H Beijnen; Martin Schutten; Marchina E van der Ende Journal: Clin Pharmacokinet Date: 2003 Impact factor: 6.447
Authors: Quirine Fillekes; Veronica Mulenga; Desiré Kabamba; Chipepo Kankasa; Margaret J Thomason; Adrian Cook; Alex Ferrier; Chifumbe Chintu; A Sarah Walker; Diana M Gibb; David M Burger Journal: AIDS Date: 2012-09-10 Impact factor: 4.177
Authors: Jane C Ellis; Rafaella F A L'homme; Fiona M Ewings; Veronica Mulenga; Frank Bell; Regina Chileshe; Elizabeth Molyneux; Julia Abernethy; Joep J G van Oosterhout; Chifumbe Chintu; A Sarah Walker; Diana M Gibb; David M Burger Journal: Antivir Ther Date: 2007
Authors: Andrzej Bienczak; Adrian Cook; Lubbe Wiesner; Veronica Mulenga; Cissy Kityo; Addy Kekitiinwa; A Sarah Walker; Andrew Owen; Diana M Gibb; David Burger; Helen McIlleron; Paolo Denti Journal: J Antimicrob Chemother Date: 2016-10-05 Impact factor: 5.790